Phase I results reported at ASCO show Semafore’s PI3K inhibitor SF1126 show the drug to be well tolerated
Filed under: kinase | Tagged: kinase, phase I, PI3K, Semafore, SF-1126, SF1126 | Leave a Comment »
Semafore report on Phase I trials with PI3K inhibitor SF1126
Posted on June 4, 2008 by crimsoncanary
